Evaluation of imipenem/cilastatin for treatment of infection in an elderly population. 1988

M D Smith, and C Bielawska, and M C Kelsey, and G Rai, and N B Deaney
Department of Microbiology, Whittington Hospital, London, UK.

Eighty-seven episodes of infection occurring in 83 patients were treated with imipenem as the sole antibiotic (1.5-4 g daily). All patients were aged 65 years or over, many with other non-infective diseases. A favourable clinical outcome (infection cured or improved) was obtained in 88% of cases. Of the 37 patients who were microbiologically evaluable, a favourable clinical outcome occurred in 92% and a favourable bacteriological outcome (pathogen eradicated or suppressed) occurred in 86% of cases. There were 13 deaths amongst the study group, which might be expected in an ill elderly population. None of the deaths was thought attributable to imipenem. Minor clinical side effects occurred in 10.6%, and one patient sustained a cerebral ischaemic episode and fits, possibly related to imipenem. No serious changes were detected in laboratory parameters.

UI MeSH Term Description Entries
D008297 Male Males
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077728 Cilastatin, Imipenem Drug Combination Combination of imipenem and cilastatin that is used in the treatment of bacterial infections; cilastatin inhibits renal dehydropeptidase I to prolong the half-life and increase the tissue penetration of imipenem, enhancing its efficacy as an anti-bacterial agent. Imipenem - Cilastatin,Imipenem - Cilastatin Sodium,Imipenem Cilastatin,Imipenem Cilastatin Sodium,Imipenem-Cilastatin,Imipenem-Cilastatin Sodium,Imipenem-Cilastatin, Sodium Salt,MK 0787-MK 0791 mixture,MK 787-MK 791 mixture,Primaxin,Thienam,Tienam 500,Zienam,Cilastatin, Imipenem,Imipenem Cilastatin, Sodium Salt,MK 0787 MK 0791 mixture,MK 787 MK 791 mixture
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria

Related Publications

M D Smith, and C Bielawska, and M C Kelsey, and G Rai, and N B Deaney
June 1986, The Japanese journal of antibiotics,
M D Smith, and C Bielawska, and M C Kelsey, and G Rai, and N B Deaney
April 1988, The Journal of antimicrobial chemotherapy,
M D Smith, and C Bielawska, and M C Kelsey, and G Rai, and N B Deaney
April 1990, Presse medicale (Paris, France : 1983),
M D Smith, and C Bielawska, and M C Kelsey, and G Rai, and N B Deaney
April 1991, DICP : the annals of pharmacotherapy,
M D Smith, and C Bielawska, and M C Kelsey, and G Rai, and N B Deaney
February 1993, Zeitschrift fur Gastroenterologie,
M D Smith, and C Bielawska, and M C Kelsey, and G Rai, and N B Deaney
December 1986, The Journal of antimicrobial chemotherapy,
M D Smith, and C Bielawska, and M C Kelsey, and G Rai, and N B Deaney
April 1990, Presse medicale (Paris, France : 1983),
M D Smith, and C Bielawska, and M C Kelsey, and G Rai, and N B Deaney
October 1984, European journal of clinical microbiology,
M D Smith, and C Bielawska, and M C Kelsey, and G Rai, and N B Deaney
August 1988, Lancet (London, England),
M D Smith, and C Bielawska, and M C Kelsey, and G Rai, and N B Deaney
September 1992, Obstetrics and gynecology clinics of North America,
Copied contents to your clipboard!